[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632647":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":30,"responsibleParty":140,"collaborators":142,"id":155,"slug":20,"hasResults":156,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":162,"sex":163,"minAge":164,"maxAge":165,"enrollmentInfo":166,"targetDuration":20,"studyType":169,"phases":170,"briefSummary":172,"conditions":173,"keywords":176,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":189},{"fullName":5,"class":6},"University of Colorado, Denver","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Psilocybin","EXPERIMENTAL","Two escalating doses of psilocybin 30 days apart",[13],"Drug: Psilocybin (Usona Institute)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Psilocybin (Usona Institute)","Evaluate the safety and tolerability of psychedelic administration in two cohorts of healthy older adults.\n\n* Cohort 1a Psilocybin Moderate Dose: 2 doses of oral psilocybin (10mg and then 25mg) 30 days apart.\n* Cohort 1b Psilocybin High Dose: 2 doses of oral psilocybin (15mg and then 30mg) 30 days apart.",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Mary P Mancuso, MA (dual degrees)","CONTACT","3037245729","inspire@cuanschutz.edu",{"name":28,"role":24,"phone":20,"phoneExt":20,"email":29},"Lila Harris, BS","lila.m.harris@cuanschutz.edu",[31,51,69,90,106,124],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"University of California San Francisco (UCSF) Department of Neurology","RECRUITING","San Francisco","California","94158","United States",{"type":39,"coordinates":40},"Point",[41,42],-122.41942,37.77493,{"lat":42,"lon":41},[45,49],{"name":46,"role":24,"phone":47,"phoneExt":20,"email":48},"Jennifer Mitchell, PhD","510-985-3522","psy.elder@ucsf.edu",{"name":46,"role":50,"phone":20,"phoneExt":20,"email":20},"PRINCIPAL_INVESTIGATOR",{"facility":52,"status":33,"city":53,"state":54,"zip":55,"country":37,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"University of Colorado Anschutz Medical Campus","Aurora","Colorado","80045",{"type":39,"coordinates":57},[58,59],-104.83192,39.72943,{"lat":59,"lon":58},[62,65,67],{"name":63,"role":24,"phone":64,"phoneExt":20,"email":26},"Mary Mancuso, MS","303-724-5729",{"name":66,"role":24,"phone":20,"phoneExt":20,"email":20},"Lila Harris, BA",{"name":68,"role":50,"phone":20,"phoneExt":20,"email":20},"Stacy Fischer, MD",{"facility":70,"status":33,"city":71,"state":72,"zip":73,"country":37,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Emory University Brain Health Center","Atlanta","Georgia","30329",{"type":39,"coordinates":75},[76,77],-84.38798,33.749,{"lat":77,"lon":76},[80,84,88],{"name":81,"role":24,"phone":82,"phoneExt":20,"email":83},"Tanja Mletzko, MA","404-778-6663","study@emory.edu",{"name":85,"role":24,"phone":86,"phoneExt":20,"email":87},"Joyelle Van Eron, MPH","404-727-8966","jvanero@emory.edu",{"name":89,"role":50,"phone":20,"phoneExt":20,"email":20},"Ali John Zarrabi, MD",{"facility":91,"status":33,"city":92,"state":93,"zip":94,"country":37,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"Dana-Farber Cancer Institute","Boston","Massachusetts","02215",{"type":39,"coordinates":96},[97,98],-71.05977,42.35843,{"lat":98,"lon":97},[101,104],{"name":102,"role":24,"phone":20,"phoneExt":20,"email":103},"Gabriel Najarian","patresearch@dfci.harvard.edu",{"name":105,"role":50,"phone":20,"phoneExt":20,"email":20},"Yvan Beaussant, MD",{"facility":107,"status":108,"city":109,"state":110,"zip":111,"country":37,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"University of Nebraska Medical Center","NOT_YET_RECRUITING","Omaha","Nebraska","68105",{"type":39,"coordinates":113},[114,115],-95.94043,41.25626,{"lat":115,"lon":114},[118,122],{"name":119,"role":24,"phone":120,"phoneExt":20,"email":121},"Jennifer Wettschreck, MS","402-559-3342","jemurray@unmc.edu",{"name":123,"role":50,"phone":20,"phoneExt":20,"email":20},"Lou Lukas, MD",{"facility":125,"status":108,"city":126,"state":126,"zip":127,"country":37,"cosmosGeoPoint":128,"geoPoint":132,"contacts":133},"New York University Langone Health, Center for Psychedelic Medicine","New York","10016",{"type":39,"coordinates":129},[130,131],-74.00597,40.71427,{"lat":131,"lon":130},[134,138],{"name":135,"role":24,"phone":136,"phoneExt":20,"email":137},"Denise Balili, MS","646-501-2623","denise.balili@nyulangone.org",{"name":139,"role":50,"phone":20,"phoneExt":20,"email":20},"Stephen Ross, MD",{"type":141,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[143,146,148,150,151,153],{"name":144,"class":145},"National Institute on Aging (NIA)","NIH",{"name":147,"class":6},"University of California, San Francisco",{"name":149,"class":6},"Emory University",{"name":91,"class":6},{"name":152,"class":6},"NYU Langone Health",{"name":154,"class":6},"University of Nebraska","100632647",false,"NCT07516405","Safety and Tolerability Trial of Psilocybin in Healthy Older Adults","A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older Adults","Psil-Pk","Inclusion Criteria:\n\n* Aged 65-85 years \\& be male, female, or non-binary\n* Generally healthy\n* Have an identified support person\n* Capacity to Consent\n\nExclusion Criteria:\n\n* Unstable medical condition\n* Risk for hypertensive crisis (screening blood pressure \\>140\u002F90 mmHg)\n* Significant central nervous system (CNS) pathology\n* Primary psychotic or affective psychotic disorders\n* Family history of psychotic or serious bipolar spectrum illnesses\n* High risk of adverse emotional or behavioral reaction\n* Active substance use disorders (SUDs)\n* Extensive use of serotonergic hallucinogens\n* High risk of completed suicide\n* History of hallucinogen persisting perception disorder (HPPD)\n* Concurrent Medications: centrally-acting serotonergic agents; antipsychotics; certain mood stabilizers, aldehyde dehydrogenase inhibitors; significant inhibitors of UGT 1A9 or UGT 1A10\n* Certain psychiatric conditions\n* Presence of relevant finding (psychological, physical symptom, medication) prior to dosing that would make a participant unsuitable for the study",true,"ALL","65 Years","85 Years",{"count":167,"type":168},40,"ESTIMATED","INTERVENTIONAL",[171],"PHASE1","This study plans to learn more about the safety and tolerability of psychedelic administration (psilocybin) in healthy older adults ages 65-85.",[174,175],"Healthy Volunteer","Older Adults (65-85 Years)",[177,178,179],"healthy older adults ages 65-85","psilocybin safety","psilocybin tolerability","2026-06-29",{"date":182,"type":183},"2026-06-30","ACTUAL",{"date":185,"type":183},"2026-04-01",{"date":187,"type":168},"2028-03",{"name":5,"class":6},6]